This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1 and ZRSR2. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.
Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the NeoTYPE AML Prognostic Profile. It is reported separately from the NeoTYPE Profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.
Molecular profiling with the NeoTYPE AML Prognostic Profile is appropriate for AML patients with intermediate-risk cytogenetic abnormalities, which is a heterogeneous group. This Profile can refine and improve risk stratification by confirming intermediate risk or reclassifying patients to more favorable or unfavorable risk categories. This change in risk classification may have therapeutic implications. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.
- Bone marrow (Preferred): 2 mL in EDTA tube.
- Peripheral blood: 5 mL in EDTA tube.
- FFPE tissue: Paraffin block. Alternatively, send 1 H&E slide plus 10-14 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative is the recommended fixative. Do not use zinc or mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note: Test in TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
14 days